Table 1.
n (%) | |
---|---|
Patients | 207 |
Age | |
30 years and younger | 20 (9.7) |
40 years | 69 (33.3) |
50 years | 86 (41.5) |
60 years and older | 32 (15.5) |
Breast cancer subtypes | |
HR-positive/HER2-positive | 69 (33.3) |
HR-positive/HER2-negative | 51 (24.6) |
HR-negative/HER2-positive | 28 (13.5) |
HR-negative/HER2-negative | 28 (13.5) |
Unknown | 31 (15.0) |
Breast cancer status | |
Operated, without recurrence/metastasis | 162 (78.3) |
Operated, with recurrence/metastasis | 37 (17.9) |
Unoperated, without recurrence/metastasis | 3 (1.4) |
Unoperated, with recurrence/metastasis | 5 (2.4) |
Drug therapy | |
Chemotherapy | 195 (94.2) |
Hormonal therapy | 132 (63.8) |
Targeted therapy | 61 (29.5) |
Physicians | 185 |
Departments | |
Department of breast oncology/surgery | 81 (43.8) |
Department of general surgery | 81 (43.8) |
Department of oncology | 23 (12.4) |
Affiliated institutions | |
University hospitals | 45 (24.3) |
Designated cancer care hospitals | 54 (29.2) |
General hospitals | 78 (42.2) |
Other | 8 (4.3) |
Nursesa | 150 |
Hospital wards | 67 (44.7) |
General outpatient units | 48 (32.0) |
Outpatient chemotherapy units | 45 (30.0) |
Breast cancer outpatient units | 13 (8.7) |
Home visit nursing | 6 (4.0) |
Numbers in italics represent the total number of participants in each group
aSome nurses had more than one affiliation; hence, the numbers by affiliation type were summed to more than 150